The evolving story of the RAAS in hypertension, diabetes and CV disease – moving from macrovascular to microvascular targets
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The phylogenetically old renin‐angiotensin‐system (RAS) was originally described as a circulating hormonal system and a main cardiovascular regulator. However, there also exist ‘local RASs’ which are situated in cardiovascular as well as non‐cardiovascular tissues where they are involved in physiological and patho‐physiological processes such as inflammation, fibrosis, proliferation or apoptosis. Local RASs are activated in diabetes, preferentially in organs affected by hyperglycaemic injury such as the kidney or the retina. Increased renal or retinal Ang II levels may contribute to diabetic tissue injury in two ways: (i) by stimulating the angiotensin AT1‐receptor and downstream pathological chains of events and (ii) by bidirectional interaction with the ‘classical’ hyperglycaemia‐induced pathobiochemical pathways (oxidative stress, generation of advanced glycation end products, increased polyol pathway flux, activation of protein kinase C, increased hexosamine pathway flux). The involvement of the RAS in the pathomechanisms underlying diabetic end organ damage suggests pharmacological RAS inhibition as a therapeutic approach in these disorders. This assumption has been supported by numerous animal studies. Clinically, RAS inhibition is currently the first line, guideline‐approved treatment in diabetic nephropathy. The recently published DIRECT, RASS and AdRem studies provided evidence that RAS inhibition may also be beneficial in diabetic retinopathy; however, evidence for RAS‐inhibition in retinopathy is still much weaker than for nephropathy. The present article reviews the emerging knowledge about cardiovascular and non‐cardiovascular effects of the RAS with an emphasis on the mechanisms of RAS involvement and pharmacological RAS inhibition in diabetic end organ damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Physiology of Local Renin-Angiotensin Systems
Paul, M., Poyan Mehr, A., & Kreutz, R. (2006) · Physiological Reviews · doi:10.1152/physrev.00036.2005 · Cited by 1,739
Standards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Renal and retinal effects of enalapril and losartan in type 1 diabetes
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808400 · Cited by 791
Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies
Förstermann, U. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1211 · Cited by 576
Sjølie, A. K., Klein, R., Porta, M., Orchard, T., Fuller, J., Parving, H. H., Bilous, R., & Chaturvedi, N. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61411-7 · Cited by 435
Toma, I., Kang, J. J., Sipos, A., Vargas, S., Bansal, E., Hanner, F., Meer, E., & Peti-Peterdi, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33293 · Cited by 322
Coughlan, M. T., Thallas-Bonke, V., Pete, J., Long, D. M., Gasser, A., Tong, D. C. K., Arnstein, M., Thorpe, S. R., Cooper, M. E., & Forbes, J. M. (2007) · Endocrinology · doi:10.1210/en.2006-1300 · Cited by 124
Cited by
Mechanisms of macular edema: Beyond the surface
Daruich, A., Matet, A., Moulin, A., Kowalczuk, L., Nicolas, M., Sellam, A., Rothschild, P.-R., Omri, S., Gélizé, E., Jonet, L., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.006 · Cited by 708
Oxidative stress and the etiology of insulin resistance and type 2 diabetes
Henriksen, E. J., Diamond-Stanic, M. K., & Marchionne, E. M. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.12.005 · Cited by 600
The renin‐angiotensin system: a link between obesity, inflammation and insulin resistance
Kalupahana, N. S., & Moustaid‐Moussa, N. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00942.x · Cited by 276
Ariza, A. C., Deen, P. M. T., & Robben, J. H. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00022 · Cited by 211
“…ERK1/2 phosphorylation is associated with proliferation of tubular cells and the development of tubulo-interstitial fibrosis (Sakai et al., 2005; Steckelings et al., 2009) and the SUCNR1 has been postulated to be instrumental in the development of fibrosis in diabetic nephropathy and…”
BackgroundRuggenenti, P., Abbate, M., Ruggiero, B., Rota, S., Trillini, M., Aparicio, C., Parvanova, A., Petrov Iliev, I., Pisanu, G., Perna, A., et al. (2017) · Diabetes · doi:10.2337/db16-0607 · Cited by 95
Metadata
- Authors
- Steckelings, U. M., Rompe, F., Kaschina, E., & Unger, T.
- Venue
- Fundamental & Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2009-11-10
- Volume
- 23
- Issue
- 6
- Pages
- 693-703
- ISSN
- 0767-3981 (ISSN-L)
- 1472-8206
- OpenAlex
- W2092808370
- Cited by
- 92
- References
- 7
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The evolving story of the RAAS in hypertension, diabetes and CV disease – moving from macrovascular to microvascular targets. https://app.cochat.ai/papers/10.1111/j.1472-8206.2009.00780.x
- The paper
- Steckelings, U. M., Rompe, F., Kaschina, E., & Unger, T. (2009). The evolving story of the RAAS in hypertension, diabetes and CV disease – moving from macrovascular to microvascular targets. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/j.1472-8206.2009.00780.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.